• 

  Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases

  Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches.

• 

  Three decades of giving: Announcing the Calibr-Skaggs Institute for Innovative Medicines

  The ALSAM Foundation, founded by the Skaggs family, provides lasting gift to Scripps Research’s drug discovery and development arm.

• 

  100 years of Science Changing Life: Scripps Research celebrates a century of transforming human health

  For the last century, institute leaders and renowned scientists have made Scripps Research what it is today: the world’s leading independent and nonprofit biomedical research institute at the forefront of innovation.

• 

  Calibr announces license agreement with Gilead to develop a long-acting HIV antiviral agent for treatment in combination with lenacapavir

  Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical care.  A Phase 1 trial has been initiated to evaluate GS-1614 - a novel prodrug of a nucleoside reverse transcriptase translocation inhibitor (NRTTI).

• 

  Life science entrepreneur Gene Lay joins Scripps Research Board of Directors

  Lay, founder of the global biotech company BioLegend, brings invaluable experience as an industry leader and innovator. 

• 

  Numerous Scripps Research scientists named Highly Cited Researchers

  Clarivate’s annual, global list represents researchers who have demonstrated significant and broad influence in their field of research.

• 

  AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

  The expanded strategic collaboration will advance several innovative assets across AbbVie’s core therapeutic growth areas including immunology, oncology, neuroscience.

• 

  Calibr launches first-in-human phase 1 clinical trial in healthy volunteers evaluating PDM608, an investigative drug developed for the treatment of neurodegenerative diseases

  Calibr scientists engineered a cytokine protein that has shown evidence of providing neuroprotective effects to Parkinson’s disease patients.

• 

  Scripps Research awarded $9.8 million by NIH to address deadly bacterial infections

  The program grant will support the development of high-affinity antibodies that can target skin and lung infections, as well as sexually transmitted diseases.

• 

  Scripps Research mourns passing of leading organic chemist Albert Eschenmoser

  Eschenmoser pioneered key reactions in synthetic chemistry and shaped the understanding of how life may have first originated on Earth.